Caxton Associates (UK)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Caxton Associates (UK)’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-214,783	Closed	-$28.3M	–	972
2025 Q1	$28.3M	Buy	+214,783	New	+$26.8M	0.99%	18

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caxton Associates (UK)'s ITCI Position: Q2 2025 in Review

Caxton Associates (UK) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 214,783 shares — an estimated $28.3M sold.

Caxton Associates (UK) first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $28.3M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Caxton Associates (UK) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Caxton Associates (UK) sold 214,783 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $28.3M.
Caxton Associates (UK) first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Caxton Associates (UK)'s Intra-Cellular Therapies Inc. position peaked at $28.3M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Caxton Associates (UK)'s 13F filing for Q2 2025, filed 15 Aug 2025.